Viking Therapeutics (VKTX) Retained Earnings: 2014-2025
Historic Retained Earnings for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to -$689.9 million.
- Viking Therapeutics' Retained Earnings fell 52.46% to -$689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$689.9 million, marking a year-over-year decrease of 52.46%. This contributed to the annual value of -$487.9 million for FY2024, which is 29.10% down from last year.
- Viking Therapeutics' Retained Earnings amounted to -$689.9 million in Q3 2025, which was down 15.15% from -$599.1 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Retained Earnings ranged from a high of -$182.2 million in Q1 2021 and a low of -$689.9 million during Q3 2025.
- Its 3-year average for Retained Earnings is -$451.8 million, with a median of -$427.6 million in 2024.
- Data for Viking Therapeutics' Retained Earnings shows a maximum YoY crashed of 52.46% (in 2025) over the last 5 years.
- Viking Therapeutics' Retained Earnings (Quarterly) stood at -$223.2 million in 2021, then tumbled by 30.86% to -$292.0 million in 2022, then fell by 29.41% to -$377.9 million in 2023, then decreased by 29.10% to -$487.9 million in 2024, then crashed by 52.46% to -$689.9 million in 2025.
- Its Retained Earnings stands at -$689.9 million for Q3 2025, versus -$599.1 million for Q2 2025 and -$533.5 million for Q1 2025.